Bevacizumab in addition to standard of care did not shorten the time to improve hypoxemia in severe hypoxemic COVID-19 pneumonia in a prospective randomized controlled trial.

Conclusions Addition of BEV to SoC did not shorten the time to improve hypoxemia in severe COVID-19 pneumonia, as compared with Soc. Deaths were numerically lower in BEV. No negative safety signal was observed.

Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Cadranel, J., Rolland-Debord, C., Labbe, V., Tuffet, S., Planquette, B., Teboul, J.-L., Jouffroy, R., Guidet, B., Voiriot, G., Hindre, R., Saval, L., Schmidt, J., Darmon, M., Marey, J., Mekontso-Dessap, A., Taille, C., Giroux-Leprieur, E., Geny, F., Mayau Tags: Respiratory infections and bronchiectasis Source Type: research